Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 12301 - 12325 of 12437 in total
Transplantation with human umbilical cord blood mononuclear cells (HUCBC) has demonstrated promising results in various disease states. While some of the positive results are credited to HUCBCs’ differentiation potential, the growth factors and cytokines these cells secrete are also implicated. When HUCBCs secrete growth factors and anti-inflammatory cytokines, they are...
Investigational
Matched Description: … While some of the positive results are credited to HUCBCs’ differentiation potential, the growth factors …
IMM-101 is a heat-inactivated immune-activating mycobacterial product. It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma [PMID: 21930686; PMID: 30107850; PMID: 27599039]. Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help...
Investigational
Matched Description: … As of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the …
Sugemalimab is a fully human, full-length IgG4 monoclonal anti-PD-L1 antibody discovered by CStone Pharmaceuticals and being investigated against relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) in adult patients and T-cell lymphoma.[L32868, L32873] It has been granted the Breakthrough Therapy Designation by the FDA to treat R/R ENKTL...
Investigational
Matched Description: … [L32868] Sugemalimab is under investigation in clinical trial NCT03802591 (A Study of CS1001 in Subjects …
Covax-19™, a protein-based vaccine, was developed through partnership between APC and Vaxine. It uses an insect-cell-produced recombinant SARS-CoV-2 spike protein and Vaxine’s adjuvant, Advax-SM. This adjuvant is designed to circumvent high fevers, fatigue, and aches experienced with other vaccines using more traditional adjuvants. Covax-19™ was tested in animal studies, and...
Investigational
Matched Description: … As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073 …
AC-100 is a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells (a fragment from matrix extracellular phosphoglycoprotein). It is being developed by Acologix, Inc.
Investigational
PBI-1402 is a small molecule synthetic compound with oral Bioavailability. The compound activates neutrophils, enhancing their survival and activation with comparable efficacy to GM-CSF, G-CSF and EPO, which are currently used to treat anemia. However, it has been shown that when co-administered with these compounds, effects are additive, making PBI-1402...
Investigational
Matched Description: … making PBI-1402 an excellent candidate for combination therapy and asserting its independent mechanism of
Cathinone is a monoamine alkaloid found in the shrub Catha edulis (Khat). Closely related to ephedrine, cathine and other amphetamines, it is probably the main contributor to the stimulant effect of Catha edulis. Cathinone differs from many other amphetamines in that its structure is a ketone. Other amphetamines to share...
Illicit
Matched Description: … ephedrine, cathine and other amphetamines, it is probably the main contributor to the stimulant effect of
HY10275 is a novel compound specifically designed to modulate two key neurobiological mechanisms that interfere with the sleeping process. HY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are known to impact the ability to fall asleep and stay asleep. HY10275 was rationally designed to...
Investigational
Matched Description: … This dual-acting receptor activity and the lack of affinity for undesired off- target receptors are thought …
COVID-19 convalescent plasma is plasma collected from patients who have acquired and subsequently recovered from COVID-19 and which contains antibodies against the causative agent SARS-CoV-2. This investigational COVID-19 treatment is currently available through three main pathways: use in registered clinical trials, use through the expanded access COVID-19 protocol (21 CFR...
Investigational
Matched Description: … [L14333] Although there are no formal clinical trial results for the safety or efficacy of COVID-19 …
AVE9633 is an anti-CD33 monoclonal antibody-DM4 conjugate.
Investigational
PRLX 93936 is selectively toxic to cancer cells.
Investigational
ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.
Investigational
NasoVAX contains replication-deficient adenovirus vectors in suspension. It is a vaccine administered through a nasal spray that expresses influenza hemagglutinin in nasal epithelial cells . Created by Altimmune, Inc., NasoVAX is currently being developed for seasonal and pandemic use as it can activate humoral and cellular immune responses. The compound...
Investigational
Matched Description: … As of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in …
Tabelecleucel is an innovative therapy that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells (CTLs). It is produced by mixing T-cells with B-cells that have been infected with the Epstein-Barr virus (EBV). Both T-cells and B-cells are obtained from the same donor, and T-cells are grown to increase their numbers....
Investigational
Matched Description: … for Human Use (CHMP) recommended tabelecleucel be granted marketing authorization for the treatment of
Galiximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.
Investigational
CGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis.
Investigational
MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
Investigational
Cambinol is a beta-naphtol derivative that inhibits NAD-dependant deacetylases to reduce cell survival under stress. This activity is currently being investigated for its use as a cancer treatment.
Experimental
Bimoclomol is an investigational drug that induces stress proteins and has cytoprotective effects.
Investigational
AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.
Investigational
Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic. Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.[A257048,A257053]
Investigational
TRC093 is a recombinant humanized IgG1k monoclonal antibody.
Investigational
Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.
Investigational
Investigational
Human amniotic fluid is the liquid surrounding the human embryo and fetus. Physically, the fluid provides protection through cushioning. Chemically, the fluid provides protection through its inherent antibacterial properties. The fluid contains carbohydrates, proteins, lipids, electrolytes, urea, immunoglobulins, growth factors, and vitamins.[L16373,L16378]
Investigational
Displaying drugs 12301 - 12325 of 12437 in total